$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

$zntl Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000172516022000053 Filed on February 24, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.754M	$8.872M	$10.36M
YoY Change	-9.01%	-12.16%	4.46%
% of Gross Profit
Research & Development	$38.44M	$54.00M	$44.77M
YoY Change	30.21%	118.88%	156.53%
% of Gross Profit
Depreciation & Amortization	$209.0K	$137.0K	$119.0K
YoY Change	596.67%	168.63%	213.16%
% of Gross Profit
Operating Expenses	$48.19M	$62.87M	$55.13M
YoY Change	19.75%	80.83%	101.39%
Operating Profit	-$48.19M	-$62.87M	-$55.13M
YoY Change	19.75%	80.83%	101.39%
Interest Expense	$88.00K	$99.00K	$115.0K
YoY Change	-72.5%	-17.5%	43.75%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$48.11M	-$11.19M	-$55.02M
YoY Change	20.47%	-67.71%	101.59%
Income Tax	$159.0K	-$697.0K	$45.00K
% Of Pretax Income
Net Earnings	-$50.06M	-$4.191M	-$54.57M
YoY Change	24.21%	-87.87%	103.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.11	-$0.09	-$1.34
Diluted Earnings Per Share	-$1.11	-$0.09	-$1.34
COMMON SHARES
Basic Shares Outstanding	44.98M shares	44.61M shares	40.74M shares
Diluted Shares Outstanding	44.98M shares	44.61M shares	40.74M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$339.9M	$366.8M	$250.9M
YoY Change	0.41%	-0.17%	7.59%
Cash & Equivalents	$59.71M	$40.81M	$49.17M
Short-Term Investments	$280.2M	$326.0M	$201.7M
Other Short-Term Assets	$10.88M	$10.67M	$8.544M
YoY Change	75.47%	105.12%	64.31%
Inventory
Prepaid Expenses
Receivables	$4.000K	$108.0K	$5.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$350.8M	$377.6M	$259.4M
YoY Change	1.64%	1.3%	8.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.148M	$4.698M	$2.251M
YoY Change	641.4%	897.45%	367.98%
Goodwill	$3.736M	$3.736M	$3.736M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$37.50M	$39.30M
YoY Change
Other Assets	$9.667M	$9.063M	$8.531M
YoY Change	124.81%	61.84%	136.97%
Total Long-Term Assets	$103.7M	$57.52M	$24.51M
YoY Change	407.25%	180.61%	30.83%
TOTAL ASSETS
Total Short-Term Assets	$350.8M	$377.6M	$259.4M
Total Long-Term Assets	$103.7M	$57.52M	$24.51M
Total Assets	$454.5M	$435.1M	$284.0M
YoY Change	24.33%	10.64%	10.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.59M	$8.046M	$8.273M
YoY Change	33.82%	47.99%	96.18%
Accrued Expenses	$32.35M	$31.37M	$25.30M
YoY Change	62.26%	69.85%	122.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.94M	$39.42M	$33.58M
YoY Change	53.64%	64.87%	115.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.46M	$0.00	$296.0K
YoY Change	3952.78%	-100.0%	-76.55%
Total Long-Term Liabilities	$44.46M	$0.00	$296.0K
YoY Change	3952.78%	-100.0%	-76.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.94M	$39.42M	$33.58M
Total Long-Term Liabilities	$44.46M	$0.00	$296.0K
Total Liabilities	$90.03M	$41.09M	$36.35M
YoY Change	179.77%	49.95%	88.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$359.6M	-$309.5M	-$305.3M
YoY Change	79.03%	92.8%	142.35%
Common Stock	$45.00K	$45.00K	$41.00K
YoY Change	9.76%	9.76%	13.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$364.0M	$393.4M	$223.8M
YoY Change
Total Liabilities & Shareholders Equity	$454.5M	$435.1M	$284.0M
YoY Change	24.33%	10.64%	10.4%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$50.06M	-$4.191M	-$54.57M
YoY Change	24.21%	-87.87%	103.2%
Depreciation, Depletion And Amortization	$209.0K	$137.0K	$119.0K
YoY Change	596.67%	168.63%	213.16%
Cash From Operating Activities	-$37.02M	-$33.49M	-$46.11M
YoY Change	35.31%	62.81%	109.31%
INVESTING ACTIVITIES
Capital Expenditures	-$2.191M	-$2.661M	-$815.0K
YoY Change	231.97%	6552.5%	2616.67%
Acquisitions
YoY Change
Other Investing Activities	$45.46M	-$138.8M	$67.43M
YoY Change	-606.21%	0.68%	-149.13%
Cash From Investing Activities	$43.27M	-$141.4M	$66.60M
YoY Change	-548.36%	2.58%	-148.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.27M	166.6M	-316.0K
YoY Change	-2179.15%	6.84%	-100.16%
NET CHANGE
Cash From Operating Activities	-37.02M	-33.49M	-46.11M
Cash From Investing Activities	43.27M	-141.4M	66.60M
Cash From Financing Activities	12.27M	166.6M	-316.0K
Net Change In Cash	18.51M	-8.363M	20.17M
YoY Change	-149.24%	226.68%	-37.68%
FREE CASH FLOW
Cash From Operating Activities	-$37.02M	-$33.49M	-$46.11M
Capital Expenditures	-$2.191M	-$2.661M	-$815.0K
Free Cash Flow	-$34.83M	-$30.83M	-$45.30M
YoY Change	30.45%	50.17%	105.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001725160
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39263
CY2021	dei	Entity Registrant Name EntityRegistrantName	Zentalis Pharmaceuticals, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3607803
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1359 Broadway
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1710
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2021	dei	City Area Code CityAreaCode	212
CY2021	dei	Local Phone Number LocalPhoneNumber	433-3791
CY2021	dei	Security12b Title Security12bTitle	Common stock,$0.001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	ZNTL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1760000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45562783	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59714000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54951000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280173000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	283554000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	417000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10636000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6182000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	243000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	350770000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	345104000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8148000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1099000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44691000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2520000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	7040000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2976000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	3736000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3736000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	8800000	USD
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	37495000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2627000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1320000	USD
CY2021Q4	us-gaap	Assets Assets	454507000	USD
CY2020Q4	us-gaap	Assets Assets	365555000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11590000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8661000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32354000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19940000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	43944000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28601000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1622000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2480000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44459000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1097000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	90025000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	32178000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45490764	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45490764	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41040286	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41040286	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	723593000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	509339000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-125000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	36000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359559000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-200834000	USD
CY2021Q4	us-gaap	Members Equity MembersEquity	363954000	USD
CY2020Q4	us-gaap	Members Equity MembersEquity	308582000	USD
CY2021Q4	us-gaap	Members Equity Attributable To Noncontrolling Interest MembersEquityAttributableToNoncontrollingInterest	528000	USD
CY2020Q4	us-gaap	Members Equity Attributable To Noncontrolling Interest MembersEquityAttributableToNoncontrollingInterest	24795000	USD
CY2021Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	364482000	USD
CY2020Q4	us-gaap	Limited Liability Company Llc Members Equity Including Portion Attributable To Noncontrolling Interest LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest	333377000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	454507000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	365555000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175601000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	84901000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38386000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40941000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33886000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8459000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	216542000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	118787000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	46845000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-216542000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-118787000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-46845000	USD
CY2021	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	401000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-118548000	USD
CY2020	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	683000	USD
CY2019	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	482000	USD
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	51582000	USD
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-164559000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-118104000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46363000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	444000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1831000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-118548000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-46378000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7368000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-707000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-715000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117841000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-45663000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.16
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42688000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42688000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28113000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28113000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5597000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5597000	shares
CY2019	us-gaap	Profit Loss ProfitLoss	-46378000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-161000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	36000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-166254000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-118512000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-46378000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7368000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-707000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-715000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-158886000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117805000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45663000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32306000	USD
CY2019	zntl	Reclassifications Of Stock To Temporary Equity Value ReclassificationsOfStockToTemporaryEquityValue	-59830000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	617000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-715000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-45663000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-73285000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-73285000	USD
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	18424000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23146000	USD
CY2020	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	155934000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	155305000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	36000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-707000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117841000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	333377000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	333377000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35737000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	171973000	USD
CY2021	zntl	Adjustments To Additional Paid In Capital Issuance And Withholding Of Common Stock In Connection With Restricted Stock Unit Vesting Net AdjustmentsToAdditionalPaidInCapitalIssuanceAndWithholdingOfCommonStockInConnectionWithRestrictedStockUnitVestingNet	1146000	USD
CY2021	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	16899000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7149000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	545000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-161000	USD
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7368000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	364482000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-166093000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-118548000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-46378000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	544000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	160000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	111000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	8800000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18115000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-284832000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2021	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	2462000	USD
CY2020	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	0	USD
CY2019	zntl	Recognized Tax Gain On Intangible Asset Impairment RecognizedTaxGainOnIntangibleAssetImpairment	0	USD
CY2021	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	49930000	USD
CY2020	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	0	USD
CY2019	zntl	Deconsolidation Gain Loss Amount Net DeconsolidationGainLossAmountNet	0	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	35737000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	23146000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	617000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-15000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	908000	USD
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	556000	USD
CY2019	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	0	USD
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1831000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-17000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-413000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	277000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-777000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-881000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5519000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1508000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13916000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14307000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7123000	USD
CY2021	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	1347000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	352000	USD
CY2020	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	-667000	USD
CY2019	zntl	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	115000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-154093000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86825000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39143000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	363508000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	400984000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	365820000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	116910000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	USD
CY2021	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	14320000	USD
CY2020	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	USD
CY2019	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6107000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	758000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-352000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	172482000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7694000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2021	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	1146000	USD
CY2020	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	0	USD
CY2019	zntl	Share Based Payment Arrangement Net Settlement Of Restricted Stock Unit Vesting ShareBasedPaymentArrangementNetSettlementOfRestrictedStockUnitVesting	0	USD
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	18424000	USD
CY2019	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	171973000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	155305000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	14228000	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	81876000	USD
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	46000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	178521000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	360439000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81830000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6313000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11218000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42335000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56271000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67489000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25154000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62584000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56271000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67489000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	20000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	18000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	15000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	44613000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	300000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1412000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1510000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	zntl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2020	zntl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019	zntl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	795000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59714000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54951000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67246000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	243000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2627000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1320000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	243000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62584000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56271000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67489000	USD
CY2017Q4	zntl	Common Stock Conversion Ratio CommonStockConversionRatio	1
CY2020Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	190000000	USD
CY2020Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	17600000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div>Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	2900000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1300000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Sources of Supply</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to credit risk from our portfolios of cash equivalents and marketable securities. We maintain our cash and cash equivalent and marketable securities balances with major commercial banks. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and cash equivalents and marketable securities to the extent recorded on the consolidated balance sheets. We have also established guidelines to limit our exposure to credit risk by diversifying our marketable securities portfolio and placing them in investments with maturities that maintain safety and liquidity. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party manufacturers for the supply of active pharmaceutical ingredients.</span></div>
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	2500000	USD
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	37500000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	280298000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	137000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280173000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	29	security
CY2021Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	174600000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	137000000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	280173000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	258948000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	21225000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43653000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	29015000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	280173000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	283554000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	323826000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	312569000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	478000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	990000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1021000	USD
CY2021Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	403000	USD
CY2020Q4	zntl	Prepaid Software License And Maintenance PrepaidSoftwareLicenseAndMaintenance	563000	USD
CY2021Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	1808000	USD
CY2020Q4	zntl	Foreign Research And Development Credit Refund ForeignResearchAndDevelopmentCreditRefund	692000	USD
CY2021Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	11204000	USD
CY2020Q4	zntl	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	5963000	USD
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	258000	USD
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	2373000	USD
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0	USD
CY2021Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	640000	USD
CY2020Q4	zntl	Other Prepaid Expense OtherPrepaidExpense	441000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	17676000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	9158000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	7040000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2976000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10636000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6182000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8940000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1349000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	792000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	250000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8148000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1099000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000	USD
CY2021Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	18531000	USD
CY2020Q4	zntl	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	11947000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9250000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5649000	USD
CY2021Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	1480000	USD
CY2020Q4	zntl	Accrued General And Administrative Costs Current AccruedGeneralAndAdministrativeCostsCurrent	996000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1453000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	902000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	971000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	410000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	669000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32354000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19940000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021	zntl	Convertible Preferred Stock Dividends Per Share Declared ConvertiblePreferredStockDividendsPerShareDeclared	0
CY2021	zntl	Temporary Equity Automatic Conversion Feature Gross Cash Proceeds Minimum Amount Received In A Public Offering TemporaryEquityAutomaticConversionFeatureGrossCashProceedsMinimumAmountReceivedInAPublicOffering	75000000.0	USD
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5187554	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5187554	shares
CY2017Q4	zntl	Common Stock Shares Subject To Future Vesting Provisions CommonStockSharesSubjectToFutureVestingProvisions	406831	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	232684	shares
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7200000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35737000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23146000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	617000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35737000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23146000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	617000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	172355	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	34.49
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4243482	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3121221	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.45
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1527300	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	50.95
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	232684	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	30.73
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	212566000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4243482	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	33.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	212566000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1141421	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	67600000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	33.27
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	16.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8800000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2600000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1300000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y8M12D
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	45912000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3277000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6352000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6498000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6973000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7291000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	45622000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76013000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30101000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1453000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44459000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-171053000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-112827000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-46363000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4663000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5277000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-166390000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-118104000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-46363000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	550000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	410000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	561000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	426000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-120000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-736000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-2000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	18000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-858000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	18000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	444000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34941000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24802000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9730000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-931000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	273000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.003
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3167000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.068
CY2021	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Amount EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossAmount	0	USD
CY2021	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Percent EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossPercent	0
CY2020	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Amount EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossAmount	0	USD
CY2020	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Percent EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossPercent	0
CY2019	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Amount EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossAmount	4000	USD
CY2019	zntl	Effective Income Tax Reconciliation Limited Liability Company Loss Percent EffectiveIncomeTaxReconciliationLimitedLiabilityCompanyLossPercent	0
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	164000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6938000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.042
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4025000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.034
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1424000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.031
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-3307000	USD
CY2019	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.020
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-1718000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.015
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	939000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	146000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-2000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	3982000	USD
CY2021	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	-0.024
CY2020	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	2956000	USD
CY2020	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsPercent	-0.025
CY2019	zntl	Effective Income Tax Rate Reconciliation Nondeductible Expense Section162m Limitations Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSection162mLimitationsAmount	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	40899000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.246
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	27614000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.234
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14170000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.306
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-297000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	444000	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82117000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	45730000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1553000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	114678000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	892000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4123000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1691000	USD
CY2021Q4	zntl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9740000	USD
CY2020Q4	zntl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	425000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2004000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	675000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	632000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14466000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7528000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56898000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	97160000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56261000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17518000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	637000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1699000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	145000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	9481000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	502000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2463000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	7954000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19140000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3117000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1622000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2480000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	97200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56300000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1124000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	741000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	969000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	661000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	383000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	197000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	66000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	50000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2835000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1124000	USD
CY2021Q4	zntl	Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate	2600000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-158725000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117841000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-45663000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42688000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42688000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28113000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28113000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5597000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5597000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4878000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4538000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12621000	shares
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	991500	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38394000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44770000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53998000	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38439000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-55132000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-62870000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-48193000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11953000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10362000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8872000	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9754000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	50347000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	55132000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	62870000	USD
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	48193000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50347000	USD
CY2021Q1	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	99000	USD
CY2021Q2	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	115000	USD
CY2021Q3	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	99000	USD
CY2021Q4	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	88000	USD
CY2021Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2021Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2021Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	51582000	USD
CY2021Q4	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50248000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55017000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11189000	USD
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48105000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	196000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	45000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-697000	USD
CY2021Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	159000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2021Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1831000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-50444000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-55062000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-10492000	USD
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-50095000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-543000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-488000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6301000	USD
CY2021Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-36000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-49901000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-54574000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4191000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-50059000	USD
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.24
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.11
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.11
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40359000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40359000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40738000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40738000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44609000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44609000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44976000	shares
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44976000	shares
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13258000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17452000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24670000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29521000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3141000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9924000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10097000	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10724000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	16399000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	27376000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	34767000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	40245000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16399000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-27376000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34767000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-40245000	USD
CY2020Q1	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	164000	USD
CY2020Q2	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	84000	USD
CY2020Q3	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	120000	USD
CY2020Q4	zntl	Investment And Other Income Expense InvestmentAndOtherIncomeExpense	315000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16235000	USD
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	426000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-16235000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27292000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34647000	USD
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39930000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	-27292000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-34665000	USD
CY2020Q4	us-gaap	Profit Loss ProfitLoss	-40356000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-109000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-435000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-110000	USD
CY2020Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-53000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16126000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26857000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-34555000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-40303000	USD
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5601000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5601000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34353000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34353000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37959000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37959000	shares
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39936000	shares
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39936000	shares

Files In Submission

Name	View Source	Status
0001725160-22-000053-index-headers.html	Edgar Link	pending
0001725160-22-000053-index.html	Edgar Link	pending
0001725160-22-000053.txt	Edgar Link	pending
0001725160-22-000053-xbrl.zip	Edgar Link	pending
exhibit103-nonxemployeedir.htm	Edgar Link	pending
exhibit211-subsidiariesofz.htm	Edgar Link	pending
exhibit231consentofindepen.htm	Edgar Link	pending
exhibit311-zentalis10xk2021.htm	Edgar Link	pending
exhibit312-zentalis10xk2021.htm	Edgar Link	pending
exhibit321-zentalis10xk2021.htm	Edgar Link	pending
exhibit322-zentalis10xk2021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zntl-20211231.htm	Edgar Link	pending
zntl-20211231.xsd	Edgar Link	pending
zntl-20211231_cal.xml	Edgar Link	unprocessable
zntl-20211231_def.xml	Edgar Link	unprocessable
zntl-20211231_g1.gif	Edgar Link	pending
zntl-20211231_g10.gif	Edgar Link	pending
zntl-20211231_g11.gif	Edgar Link	pending
zntl-20211231_g12.gif	Edgar Link	pending
zntl-20211231_g13.gif	Edgar Link	pending
zntl-20211231_g14.gif	Edgar Link	pending
zntl-20211231_g15.gif	Edgar Link	pending
zntl-20211231_g16.gif	Edgar Link	pending
zntl-20211231_g17.gif	Edgar Link	pending
zntl-20211231_g18.gif	Edgar Link	pending
zntl-20211231_g19.gif	Edgar Link	pending
zntl-20211231_g2.gif	Edgar Link	pending
zntl-20211231_g20.gif	Edgar Link	pending
zntl-20211231_g21.gif	Edgar Link	pending
zntl-20211231_g22.gif	Edgar Link	pending
zntl-20211231_g23.gif	Edgar Link	pending
zntl-20211231_g24.gif	Edgar Link	pending
zntl-20211231_g25.gif	Edgar Link	pending
zntl-20211231_g26.gif	Edgar Link	pending
zntl-20211231_g27.gif	Edgar Link	pending
zntl-20211231_g28.gif	Edgar Link	pending
zntl-20211231_g29.gif	Edgar Link	pending
zntl-20211231_g3.gif	Edgar Link	pending
zntl-20211231_g30.gif	Edgar Link	pending
zntl-20211231_g31.gif	Edgar Link	pending
zntl-20211231_g32.gif	Edgar Link	pending
zntl-20211231_g33.gif	Edgar Link	pending
zntl-20211231_g4.gif	Edgar Link	pending
zntl-20211231_g5.gif	Edgar Link	pending
zntl-20211231_g6.gif	Edgar Link	pending
zntl-20211231_g7.gif	Edgar Link	pending
zntl-20211231_g8.gif	Edgar Link	pending
zntl-20211231_g9.gif	Edgar Link	pending
zntl-20211231_htm.xml	Edgar Link	completed
zntl-20211231_lab.xml	Edgar Link	unprocessable
zntl-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl

2021 Q4 Form 10-K Financial Statement

#000172516022000053 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL Zentalis Pharmaceuticals, Inc. Stock $zntl

2021 Q4 Form 10-K Financial Statement

#000172516022000053 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZNTL
Zentalis Pharmaceuticals, Inc. Stock $zntl